3D Investment challenges Toho poison pill as stake nears 27%

Singapore hedge fund 3D Investment Partners sought a Tokyo court injunction Thursday to block Toho Holdings' poison pill, challenging the defense against activist investors.

"If management is confident its own strategy is right, it should devote its resources to explaining that strategy to shareholders, rather than seeking support for defense measures," Manabu Matsunaka, a professor at Nagoya University Graduate School, said.

3D, Toho's largest shareholder, wants to raise its stake to 27 percent from 24 percent. The drug wholesaler's poison pill would trigger a discriminatory warrant issuance designed to dilute its holding if it acquires additional shares. Shareholders backed the measure with 54.7 percent support at the June annual general meeting.

The request to the Tokyo District Court tests whether companies can deploy such defenses against activists who are not seeking control in Japan, the world's second-largest market for activist campaigns after the United States.

3D said it has no intention of acquiring management control, arguing a 27 percent stake falls short of the level Toho has said would confer effective veto power, so the prerequisite for triggering the measure does not exist. Toho told shareholders before the June meeting that a 27 percent stake would let 3D exert significant influence and potentially pressure it to prioritize short-term gains.

Japan's anti-takeover defenses were once dominated by "pre-warning" poison pills adopted before a specific bidder emerged, but their use waned after governance reforms under former Prime Minister Shinzo Abe boosted scrutiny of shareholder voting. More recently, contingency-based poison pills targeting specific investors have increased. Advisory firm IR Japan says a record 10 such measures were adopted last year, often to prevent activist funds from raising stakes beyond roughly 20 percent, a level some companies argue can confer significant influence.

Government takeover guidelines permit poison pills aimed at giving shareholders time and information to assess a buyout bid. Critics say measures used against investors who are not seeking control risk entrenching management and undermining corporate governance. Allowing such defenses could weaken the disciplinary pressure on management from capital markets, Matsunaka said.

The ruling could set a precedent for how Japanese courts evaluate poison pill defenses, affecting merger activity, activist strategies and governance practices across listed companies. A decision favoring 3D could embolden more activist campaigns in Japan, while one for Toho would reinforce defensive measures. Investors will watch for the court's decision on the injunction in coming weeks.

This article is for informational purposes only and does not constitute investment advice.